Biogen_Logo_Standard-rgb_R.jpg
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
17 déc. 2018 07h30 HE | Biogen Inc.; Alkermes plc
DUBLIN, Ireland and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application...
First Descents Expands Programming to Serve Young Adults with Multiple Sclerosis
25 oct. 2018 09h00 HE | Velocity Global
Denver, CO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- After 17 years of helping to improve the lives of young adults with cancer through activities like kayaking, rock climbing and surfing, non-profit First...
Biogen_Logo_Standard-rgb_R.jpg
Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis
11 oct. 2018 07h30 HE | Biogen Inc.
Evidence supports potential of serum neurofilament light (sNfL) as clinically useful biomarker in MS; Biogen and Siemens Healthineers collaborate to develop sNfL blood testReal-world data add to the...
CRBP-300-196.png
Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
03 oct. 2018 09h00 HE | Corbus Pharmaceuticals Holdings, Inc.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemIntellectual property around pipeline targeting endocannabinoid...
Biogen_Logo_Standard-rgb_R.jpg
Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care
02 oct. 2018 07h30 HE | Biogen Inc.
New research further supports the long-term efficacy and well-characterized safety of leading MS productsNovel data generation initiatives aim to improve outcomes and support the continued move toward...
TMlogo.jpg
Q Therapeutics Receives Orphan Drug Designation for Transverse Myelitis
26 sept. 2018 06h00 HE | Q Therapeutics, Inc.
FDA DESIGNATION WOULD PROVIDE 7 YEARS OF MARKET EXCLUSIVITY UPON MARKET APPROVAL OF Q-CELLS® SALT LAKE CITY, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Q Therapeutics, Inc., a developer of clinical-stage...
Aphios Logo1.jpg
Aphios Pharma LLC  Announces Reg. CF Private Placement Offering
17 sept. 2018 08h00 HE | Aphios
WOBURN, Mass., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Aphios® Pharma LLC is pleased to announce the launch of a private placement offering in accordance with Regulation Crowdfunding  (Reg. CF) adopted...
FINAL_LOGO-02.jpg
AXIM® Biotechnologies to Present at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology
15 août 2018 09h00 HE | AXIM BIOTECHNOLOGIES, INC
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that the Company will be...
Adamas Pharmaceuticals Logo
Adamas Reports Second Quarter 2018 Financial Results
02 août 2018 16h01 HE | Adamas Pharmaceuticals, Inc.
- GOCOVRI™ (amantadine) extended release capsules product sales reached $7.6 million for the second quarter - EMERYVILLE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc....
Octave Bioscience Secures $14 Million Series A Financing Round
12 juil. 2018 13h30 HE | Octave Bioscience
MENLO PARK, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Octave Bioscience, the developer of a fully integrated care management solution delivering powerful insights for patients with neurodegenerative...